Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-09 5:08 pm Sale | 2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Artal International S.C.A. | 0 0.000% | -15,066,043 (Position Closed) | Filing History |
| 2023-10-10 11:35 am Purchase | 2021-12-31 | 13G | Ambrx Biopharma Inc. AMAM | HOPU Reunion Co Ltd | 38,952,409 8.900% | 38,952,409 (New Position) | Filing History |
| 2023-09-25 5:24 pm Purchase | 2023-09-14 | 13G | Ambrx Biopharma Inc. AMAM | Paradigm Biocapital Advisors LP | 25,172,784 5.700% | 25,172,784 (New Position) | Filing History |
| 2023-06-28 4:45 pm Purchase | 2023-06-27 | 13D | Ambrx Biopharma Inc. AMAM | Darwin Global Management Ltd. | 116,820,452 27.500% | 37,688,441 (+47.63%) | Filing History |
| 2023-05-25 4:39 pm Unchanged | 2023-05-23 | 13D | Ambrx Biopharma Inc. AMAM | Darwin Global Management Ltd. | 79,132,011 20.500% | 0 (Unchanged) | Filing History |
| 2023-04-27 4:05 pm Sale | 2023-04-24 | 13G | Ambrx Biopharma Inc. AMAM | COMMODORE CAPITAL LP | 31,181,983 8.100% | -4,518,017 (-12.66%) | Filing History |
| 2023-03-16 4:05 pm Purchase | 2023-03-06 | 13G | Ambrx Biopharma Inc. AMAM | D. E. Shaw & Co., L.P. | 22,050,000 8.200% | 22,050,000 (New Position) | Filing History |
| 2023-03-13 4:00 pm Purchase | 2023-03-03 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 52,500,000 17.730% | 36,145,298 (+221.01%) | Filing History |
| 2023-03-08 10:49 am Purchase | 2023-03-06 | 13D | Ambrx Biopharma Inc. AMAM | Darwin Global Management Ltd. | 79,132,011 26.400% | 26,040,588 (+49.05%) | Filing History |
| 2023-03-03 4:10 pm Purchase | 2023-02-23 | 13G | Ambrx Biopharma Inc. AMAM | COMMODORE CAPITAL LP | 35,700,000 13.200% | 9,450,000 (+36.00%) | Filing History |
| 2023-03-03 4:05 pm Purchase | 2023-02-21 | 13G | Ambrx Biopharma Inc. AMAM | COMMODORE CAPITAL LP | 26,250,000 9.700% | 26,250,000 (New Position) | Filing History |
| 2023-02-27 4:05 pm Purchase | 2023-02-16 | 13G | Ambrx Biopharma Inc. AMAM | Venrock Healthcare Capital Partners III L.P. | 26,740,000 9.900% | 26,740,000 (New Position) | Filing History |
| 2023-02-14 4:02 pm Sale | 2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM | HBM Healthcare Investments (Cayman) Ltd. | 8,400,000 3.100% | -8,456,567 (-50.17%) | Filing History |
| 2023-02-14 3:12 pm Sale | 2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 16,354,702 6.050% | -911,442 (-5.28%) | Filing History |
| 2023-02-14 09:30 am Purchase | 2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Darwin Global Management Ltd. | 53,091,423 19.600% | 2,450,000 (+4.84%) | Filing History |
| 2023-02-10 7:21 pm Unchanged | 2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Artal International S.C.A. | 15,066,043 5.600% | 0 (Unchanged) | Filing History |
| 2023-02-09 10:54 am Sale | 2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM | ADAGE CAPITAL PARTNERS GP L.L.C. | 7,191,037 2.660% | -7,000,000 (-49.33%) | Filing History |
| 2023-02-09 08:23 am Sale | 2023-02-09 | 13G | Ambrx Biopharma Inc. AMAM | FMR LLC | 18,872,448 6.981% | -7,936,866 (-29.60%) | Filing History |
| 2022-12-19 08:30 am Purchase | 2022-12-09 | 13G | Ambrx Biopharma Inc. AMAM | Darwin Global Management Ltd. | 50,641,423 18.700% | 50,641,423 (New Position) | Filing History |
| 2022-03-10 09:48 am Sale | 2022-03-09 | 13G | Ambrx Biopharma Inc. AMAM | FMR LLC | 26,809,314 10.683% | -175,861 (-0.65%) | Filing History |